Radiation and immunotherapy combo before lung cancer surgery shows promise in early trial
NCT ID NCT06191250
First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether a low dose of radiation (12 Gy in 3 fractions) combined with one dose of the immunotherapy drug durvalumab can boost the immune system's attack on lung cancer cells before surgery. The study enrolls people with stage 2 or 3 non-small cell lung cancer whose tumors are removable. Researchers will measure immune cell activity in the tumor after treatment to see if the combination works better than either approach alone.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Durvalumab (immunotherapy) and non-ablative oligofractionated radiation (low-dose radiation)
- What this could lead to
- If successful, this approach could improve immune response against lung cancer and lead to better outcomes after surgery.
- What could go wrong
- This is a very small early-phase trial with only 10 participants, so results may not apply broadly. The combination may cause side effects or fail to boost immune activity as hoped.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLINICAL STAGING T2B-3 N0-1 M0 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Health Network
Toronto, Ontario, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Direct-to-Tumor chemo blast halt advanced lung cancer?
- Smart patch and app aim to boost lung recovery after cancer surgery
- Targeted drug LDK378 takes aim at rare ROS1-driven lung cancer
- Custom-Made vaccine aims to stop lung cancer recurrence
- New study aims to tame cholesterol side effect of lung cancer drug
- New pill targets Hard-to-Treat cancers with a specific gene mutation